Five things for pharma marketers to know: Friday, May 6, 2016

Investigation says Oxycontin wears off sooner than it claims; PBMs and insurers anticipate high biosimilar prices; Valeant forms pricing committee

Post Pfizer, Allergan faces the future

Mere days after the Pfizer deal collapsed, top Allergan executives had nary an air of regret about them.

An emotional bond with patients is key, says Elemental Machines' Iyengar

At the MM&M Transforming Healthcare conference, Iyengar told attendees how to take into account a consumer's behavior and emotion when marketing medical products.

Care Angel wins MM&M Shark Tank challenge 2016

The Siri for Seniors took the top prize at the second MM&M Shark Tank for its annual healthcare conference.

Omnicom to acquire BioPharm Communications

Omnicom to acquire BioPharm Communications

Omnicom recently reorganized its health agencies under the Omnicom Health Group umbrella.

Five things for pharma marketers to know: Thursday, May 5, 2016

Five things for pharma marketers to know: Thursday, May 5, 2016

U.S. Keytruda sales miss mark; the CDC warns parents to try therapy before drugs for children with ADHD; FDA panel recommends training for opioid prescribers

Time is running out: Fill in MM&M's Agency questionnaire

Time is running out: Fill in MM&M's Agency questionnaire

Did your agency report record growth in 2015? Tell us why when you fill out the A-to-Z questionnaire for MM&M's upcoming agency issue. The deadline is Friday.

Five things for pharma marketers to know: Wednesday, May 4, 2016

Five things for pharma marketers to know: Wednesday, May 4, 2016

The FDA issues warning for certain antipsychotics; Shkreli may face more securities charges; Genentech and Stand Up to Cancer launch campaign

Five things for pharma marketers to know: Tuesday, May 3, 2016

Five things for pharma marketers to know: Tuesday, May 3, 2016

IMS and Quintiles to merge and create $17 billion firm; Biogen spins off hemophilia company; Google partners with the National Health Service

2016 Pharma Report: All the data in one place

2016 Pharma Report: All the data in one place

Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.

Spending on drugs is up, but by how much?

Spending on drugs is up, but by how much?

Total medicine spending surged to $424.8 billion in 2015, representing an increase of 12.2%. Here's why that growth figure is closer to 2.9%.

Bristol-Myers Squibb plans to spend more on DTC for Opdivo

Bristol-Myers Squibb plans to spend more on DTC for Opdivo

The drugmaker said it plans to increase its investment in DTC for the immuno-oncology drug.

Five things for pharma marketers to know: Thursday, April 28, 2016

Five things for pharma marketers to know: Thursday, April 28, 2016

Pfizer settles rebate suit; Sanofi moves to acquire Medivation; AstraZeneca sells US rights to gout drug

Senate committee condemns Valeant's business model

Senate committee condemns Valeant's business model

The Senate committee on Aging said Valeant's missteps go beyond price hikes and that its business model is fundamentally to blame.

Agency Spotlight


OPINION


Click here to learn about the Agency Issue. 

Email Newsletters